Table 2 of Dekomien, Mol Vis 2002; 8:436-441.


Table 2. Primers and conditions for PCR amplification

PCR systems to characterize the canine RCV1 gene including mutation screening. Systems designated by H: PCR primer sequences selected from the human mRNA (EMBL accession number AB001838) for the identification of exon/intron boundaries and canine gene sequences. Systems designated by I: PCR primers (on the basis of the canine RCV1 gene EMBL accession number AJ414401) to amplify the complete intron. Systems designated by M: PCR primers (on the basis of the canine RCV1 gene) for mutation analysis. Ht: Additional PCR primers used for haplotype analysis. *Nucleotide position to which the 5' end of the primer (red type) hybridizes. ** Addition of 5% DMSO.

                                                                             Restriction    Annealing
                                                          PCR Fragment       enzymes for     T/MgCl2
PCR-system   Primer sequence (5'->3')*   Location         length (bp)       SSCP analysis    (°C/mM)
----------   -------------------------   -----------   ------------------   -------------   ---------
H 1F         CCCTGTCCAAGGAGATCCT         E 1; 13       359                       -           47/2**
H 1R         CATGACGATCTCCAGCACTT        E 1; 381
I 1-331EF    TCTCGCTCTACGACGTGGA         E 1; 580      837                       -           54/2
I 1-IR       GACAGGGAACGGAGTGAAG         I 1; 1419
H 1F         CCCTGTCCAAGGAGATCCT         E 1; 13       1422                      -           46/2**
H 2R         CTTTCCAAAGTACTTCCAGATC      E 2; 483
H 2F         TTCAAAATGATCACTCCCGAGG      E 2; 388      2684                      -           48/2**
H 3R         TCATCTTTTCCTTCACTTTTTGAG    E 3; 592
I 2F         ACCGCCGAGCTCCCTGG           I 2; 2006     1774                      -           54/2**
I 2R         ATGCGGAGACACTCCCACG         I 2; 3777
I/M 2 2F     TGAGAACTGGCCTTCGAGG         I 2; 2398     1020: 208, 98, 160,      DdeI         52/1
I/M 2 2R     CGTGACTGTGGCATTCACC         I 2; 3417     13, 188, 276, 77
I/M 2Ht 2F   GGGAGGCATTCCAGAACAG         I 2; 2658     760: 30, 160, 13,        DdeI         54/1
I/M 2 2R     CGTGACTGTGGCATTCACC         I 2; 3417     188, 276, 77
M 5'-UTR1F   CTCCCTGAAGGCCAAGATG         UTR/E 1; 1    372: 184, 132,           PstI         55/1
M/Ht Kl1ER   TTCGGAAGGAAACTGGTACC        E 1; 374      56
H/M 1F       CCCTGTCCAAGGAGATCCT         E 1; 13       424: 183, 71,           NlaIII        54/1
M 1-IR       GAACCCCCTGGACCCAGGA         I 1; 709      145, 65
M 2-IF       GGAATCTGTATTTTCACCTCTG      I 1; 1483     308: 136,                DdeI         55/1
M 2-IR       CTAGGAAGACCAATCTCACT        I 2; 1790     172
M 3-IF       GTGATGGGTTGTACCCTCAG        I 2; 4019     340: 206,                MboI         55/1
M UTR 3'R    GCATGTGCACGTGCTCACG         3'-UTR; 4358  134

Dekomien, Mol Vis 2002; 8:436-441 <http://www.molvis.org/molvis/v8/a52/>
©2002 Molecular Vision <http://www.molvis.org/molvis/>
ISSN 1090-0535